Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2015 by Washington University School of Medicine
Information provided by (Responsible Party):
Washington University School of Medicine Identifier:
First received: March 8, 2006
Last updated: June 11, 2015
Last verified: June 2015
This is an observational study intended to validate results of a previous study done at the Mayo Clinic. Patients are treated with combination chemotherapy and radiation and maintained on oral Xeloda until they can receive liver transplant. A staging laparotomy is performed before chemoradiation in order to identify patients who will most benefit from the treatment and to improve outcomes.

Condition Intervention
Other: Observation data collection study.

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prospective Registry Study of Neoadjuvant Chemoradiation in Conjunction With Liver Transplantation for Cholangiocarcinoma With Induction Gemcitabine, Followed by 3D Conformal Radiation With 5-FU as a Radiosensitizer, and Maintenance Xeloda Therapy Until Liver Transplantation

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Primary (Phase I): Proportion of patients with grade 3 or 4 DLT. [ Time Frame: Approximately 5 years. ] [ Designated as safety issue: Yes ]
  • Primary (Phase II): Rate of excess toxicity, proportion of patients with stable disease, or better, response at completion of chemoradiation, and the proportion of patients who are alive at 2 years after transplant. [ Time Frame: Approximatly 5 years. ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: August 2005
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with unresectable cholangiocarcinoma.
Other: Observation data collection study.
This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic.

Inclusion Criteria:

  1. Diagnosis of cholangiocarcinoma that has been established preoperatively by at least one of the following criteria:

    1. A positive brush cytology or biopsy result obtained at the time of cholangiography;
    2. Fluorescence in situ hybridization demonstrating aneuploidy;
    3. A serum CA 19-9 value greater than 100 U/mL in the presence of a radiographically characteristic malignant stricture in the absence of cholangitis.
  2. Tumor is above the cystic duct and is unresectable.
  3. A suitable candidate for orthotopic liver transplantation as judged by a radiation oncologist, a medical oncologist, and the liver transplant team.
  4. Between ages 18 and 70 (inclusive).
  5. Willing and able to provide written informed consent.

Exclusion Criteria:

  1. Intrahepatic metastasis or other metastatic disease (except peri-hilar nodes).
  2. Prior treatment for this disease (including attempts at resection, irradiation, or chemotherapy)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00301379

Contact: William Chapman, MD 314-362-7792
Contact: Casey Rowe, MS, BS 314-362-8547

United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: William Chapman, MD    314-362-7792   
Contact: Casey Rowe, MS, BS    314-362-8547   
Principal Investigator: William C. Chapman, M.D.         
Sub-Investigator: Joel Picus, M.D.         
Sub-Investigator: Surendra Shenoy, MD         
Sub-Investigator: Jeffrey Lowell, MD         
Sub-Investigator: Jeffrey Crippin, MD         
Sub-Investigator: Mauricio Lisker-Mehlman, MD         
Sub-Investigator: Kevin Korenblat, MD         
Sub-Investigator: Benjamin Tan, MD         
Sub-Investigator: Steven Edmundowicz, MD         
Sub-Investigator: Parag Parikh, M.D.         
Sub-Investigator: Elizabeth Brunt, M.D.         
Sub-Investigator: M.B. Majella Doyle, M.D.         
Sub-Investigator: Kathryn Fowler, M.D.         
Sub-Investigator: Vamsi Narra, M.D.         
Sub-Investigator: Nael Saad, M.D.         
Sub-Investigator: Daniel Mullady, M.D.         
Sub-Investigator: Faris Murad, M.D.         
Sub-Investigator: Jaquelyn Fleckenstein, M.D.         
Sub-Investigator: Jason Wellen, M.D.         
Sub-Investigator: Yiing Lin, M.D.         
Sub-Investigator: Jeffrey R. Olsen, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
Principal Investigator: William C. Chapman, M.D. Washington University School of Medicine
  More Information

Additional Information:
Tsavaris, Inv New Drugs, 22:193, 2004;Verdarame, Anti-Cancer Drugs, 11:707,2000.
Picus, Proc ASCO, 13:208, 1994.

Responsible Party: Washington University School of Medicine Identifier: NCT00301379     History of Changes
Other Study ID Numbers: 05-0651 / 201102096
Study First Received: March 8, 2006
Last Updated: June 11, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial processed this record on December 01, 2015